TELA
TELA Bio, Inc.
Price Chart
Latest Quote
$0.80
-0.06 (-6.76%)
Current Price
| Previous Close | $0.86 |
| Open | $0.85 |
| Day High | $0.87 |
| Day Low | $0.78 |
| Volume | 93,928 |
Stock Information
| Shares Outstanding | 44.77M |
| Total Debt | $55.87M |
| Cash Equivalents | $39.54M |
| Revenue | $80.81M |
| Net Income | $-39.84M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $35.86M |
| EPS (TTM) | $-0.79 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $56.50M |
| Sales | $80.81M |
| Income | $-39.84M |
| Book/sh | $-0.12 |
| Cash/sh | $0.88 |
| Employees | 218 |
Financial Ratios
| Quick Ratio | 2.76 |
| Current Ratio | 3.61 |
Returns & Margins
| ROA | -28.72% |
| ROE | -616.62% |
| Gross Margin | 67.72% |
| Operating Margin | -55.23% |
| Profit Margin | -49.30% |
Ownership
| Insider Ownership | 8.21% |
| Institutional Ownership | 68.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.44 |
| P/S | 0.44 |
| P/B | -6.91 |
Analyst Data
| Recommendation | none |
| Target Price | $2.25 |
Technical Indicators
| SMA20 | $0.88 |
| SMA50 | $0.85 |
| SMA200 | $1.05 |
| RSI | 36.12 |
| ATR | 0.0971 |
| Shares Float | 19.48M |
| Short Float | 2.42% |
| Short Ratio | 3.35 |
| Rel Volume | 0.96 |
Performance History
| Week | -12.17% |
| Month | -6.86% |
| Quarter | +6.80% |
| 6 Months | -32.12% |
| YTD | -29.74% |
| Year | -46.60% |
| 3 Years | -92.74% |
| 5 Years | -93.72% |
| 10 Years | -94.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.80 | 106,308 |
| 2026-06-17 | $0.86 | 62,200 |
| 2026-06-16 | $0.90 | 117,900 |
| 2026-06-15 | $0.80 | 169,600 |
| 2026-06-12 | $0.86 | 127,400 |
| 2026-06-11 | $0.91 | 168,300 |
| 2026-06-10 | $0.94 | 128,200 |
| 2026-06-09 | $0.94 | 152,400 |
| 2026-06-08 | $0.85 | 146,200 |
| 2026-06-05 | $0.88 | 66,300 |
| 2026-06-04 | $0.88 | 46,500 |
| 2026-06-03 | $0.86 | 136,800 |
| 2026-06-02 | $0.91 | 77,400 |
| 2026-06-01 | $0.90 | 83,300 |
| 2026-05-29 | $0.97 | 74,600 |
| 2026-05-28 | $0.90 | 136,800 |
| 2026-05-27 | $0.87 | 118,700 |
| 2026-05-26 | $0.81 | 119,400 |
| 2026-05-22 | $0.89 | 95,700 |
| 2026-05-21 | $0.92 | 75,400 |
| 2026-05-20 | $0.95 | 135,700 |
| 2026-05-19 | $0.86 | 106,500 |
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
đ° Latest News
Earnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25
Simply Wall St. âĸ 2026-05-15T12:11:10Z
TELA Bio, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T12:30:00Z
TELA Bio Inc (TELA) Q1 2026 Earnings Call Highlights: Strong European Growth and Strategic U.S. ...
GuruFocus.com âĸ 2026-05-13T05:01:54ZTELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-12T21:15:02Z
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-11T21:25:01Z
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T21:25:03Z
TELA Bio, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-25T12:30:00Z
TELA Bio Inc (TELA) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid Strategic ...
GuruFocus.com âĸ 2026-03-25T03:02:10ZTELA Bio (TELA) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-03-24T22:01:09Z
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-24T21:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $25,934,000 | $22,812,000 | $18,341,000 | $14,374,000 |
| Cost Of Revenue | $25,934,000 | $22,812,000 | $18,341,000 | $14,374,000 |
| Total Revenue | $80,275,000 | $69,300,000 | $58,453,000 | $41,418,000 |
| Operating Revenue | $80,275,000 | $69,300,000 | $58,453,000 | $41,418,000 |
| Expenses | ||||
| Interest Expense | $5,245,000 | $5,290,000 | $5,223,000 | $4,051,000 |
| Total Expenses | $114,030,000 | $110,995,000 | $102,528,000 | $80,425,000 |
| Other Income Expense | $399,000 | $9,000,000 | $2,634,000 | $-1,238,000 |
| Other Non Operating Income Expenses | $1,287,000 | $1,420,000 | $2,634,000 | $-10,000 |
| Net Non Operating Interest Income Expense | $-5,245,000 | $-5,290,000 | $-5,223,000 | $-4,051,000 |
| Interest Expense Non Operating | $5,245,000 | $5,290,000 | $5,223,000 | $4,051,000 |
| Operating Expense | $88,096,000 | $88,183,000 | $84,187,000 | $66,051,000 |
| Selling And Marketing Expense | $63,182,000 | $64,648,000 | $59,681,000 | $43,252,000 |
| General And Administrative Expense | $15,694,000 | $14,722,000 | $14,887,000 | $13,862,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,831,000 | $-37,841,000 | $-46,664,000 | $-44,296,000 |
| Net Interest Income | $-5,245,000 | $-5,290,000 | $-5,223,000 | $-4,051,000 |
| Normalized Income | $-38,129,480 | $-45,390,680 | $-46,664,000 | $-43,068,000 |
| Net Income From Continuing And Discontinued Operation | $-38,831,000 | $-37,841,000 | $-46,664,000 | $-44,296,000 |
| Total Operating Income As Reported | $-33,755,000 | $-34,115,000 | $-44,075,000 | $-39,007,000 |
| Net Income Common Stockholders | $-38,831,000 | $-37,841,000 | $-46,664,000 | $-44,296,000 |
| Net Income | $-38,831,000 | $-37,841,000 | $-46,664,000 | $-44,296,000 |
| Net Income Including Noncontrolling Interests | $-38,831,000 | $-37,841,000 | $-46,664,000 | $-44,296,000 |
| Net Income Continuous Operations | $-38,831,000 | $-37,841,000 | $-46,664,000 | $-44,296,000 |
| Pretax Income | $-38,601,000 | $-37,985,000 | $-46,664,000 | $-44,296,000 |
| Special Income Charges | $-888,000 | $7,580,000 | $0 | $-1,228,000 |
| Operating Income | $-33,755,000 | $-41,695,000 | $-44,075,000 | $-39,007,000 |
| Gross Profit | $54,341,000 | $46,488,000 | $40,112,000 | $27,044,000 |
| Per Share | ||||
| Diluted EPS | $-0.83 | $-1.33 | $-2.04 | $-2.72 |
| Basic EPS | $-0.83 | $-1.33 | $-2.04 | $-2.72 |
| Other | ||||
| Tax Effect Of Unusual Items | $-186,480 | $30,320 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-31,458,000 | $-39,263,000 | $-40,633,000 | $-37,830,000 |
| Total Unusual Items | $-888,000 | $7,580,000 | $0 | $-1,228,000 |
| Total Unusual Items Excluding Goodwill | $-888,000 | $7,580,000 | $0 | $-1,228,000 |
| Reconciled Depreciation | $1,010,000 | $1,012,000 | $808,000 | $1,187,000 |
| EBITDA (Bullshit earnings) | $-32,346,000 | $-31,683,000 | $-40,633,000 | $-39,058,000 |
| EBIT | $-33,356,000 | $-32,695,000 | $-41,441,000 | $-40,245,000 |
| Diluted Average Shares | $46,947,932 | $28,526,441 | $22,868,663 | $16,267,678 |
| Basic Average Shares | $46,947,932 | $28,526,441 | $22,868,663 | $16,267,678 |
| Diluted NI Availto Com Stockholders | $-38,831,000 | $-37,841,000 | $-46,664,000 | $-44,296,000 |
| Tax Provision | $230,000 | $-144,000 | $0 | $0 |
| Gain On Sale Of Business | $0 | $7,580,000 | $0 | $0 |
| Other Special Charges | $888,000 | - | - | $1,228,000 |
| Research And Development | $9,220,000 | $8,813,000 | $9,619,000 | $8,937,000 |
| Selling General And Administration | $78,876,000 | $79,370,000 | $74,568,000 | $57,114,000 |
| Other Gand A | $15,694,000 | $14,722,000 | $14,887,000 | $13,862,000 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,954,000 | $26,719,000 | $16,762,000 | $11,806,000 |
| Total Assets | $81,418,000 | $86,570,000 | $78,048,000 | $67,855,000 |
| Total Non Current Assets | $5,837,000 | $8,499,000 | $6,322,000 | $5,408,000 |
| Other Non Current Assets | $750,000 | $2,541,000 | $265,000 | - |
| Non Current Deferred Assets | $0 | $140,000 | $0 | - |
| Non Current Deferred Taxes Assets | $0 | $140,000 | $0 | - |
| Goodwill And Other Intangible Assets | $1,359,000 | $1,739,000 | $2,119,000 | $2,499,000 |
| Current Assets | $75,581,000 | $78,071,000 | $71,726,000 | $62,447,000 |
| Other Current Assets | $3,373,000 | $2,522,000 | $2,098,000 | $2,015,000 |
| Inventory | $11,016,000 | $12,781,000 | $13,162,000 | $11,792,000 |
| Receivables | $10,347,000 | $10,098,000 | $9,737,000 | $6,621,000 |
| Accounts Receivable | $10,347,000 | $10,098,000 | $9,737,000 | $6,621,000 |
| Allowance For Doubtful Accounts Receivable | $-287,000 | $-275,000 | $-416,000 | $-143,000 |
| Gross Accounts Receivable | $10,634,000 | $10,373,000 | $10,153,000 | $6,764,000 |
| Cash Cash Equivalents And Short Term Investments | $50,845,000 | $52,670,000 | $46,729,000 | $42,019,000 |
| Cash And Cash Equivalents | $50,845,000 | $52,670,000 | $46,729,000 | $42,019,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $4,808,000 | - | - | - |
| Total Debt | $56,177,000 | $41,669,000 | $41,080,000 | $40,256,000 |
| Long Term Debt And Capital Lease Obligation | $55,653,000 | $41,124,000 | $40,515,000 | $39,916,000 |
| Long Term Debt | $55,653,000 | $41,124,000 | $40,515,000 | $39,916,000 |
| Current Debt And Capital Lease Obligation | $524,000 | $545,000 | $565,000 | $340,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $75,105,000 | $58,112,000 | $59,167,000 | $53,550,000 |
| Total Non Current Liabilities Net Minority Interest | $57,130,000 | $42,514,000 | $42,200,000 | $41,147,000 |
| Other Non Current Liabilities | $1,477,000 | $1,390,000 | $1,685,000 | $1,231,000 |
| Current Liabilities | $17,975,000 | $15,598,000 | $16,967,000 | $12,403,000 |
| Payables And Accrued Expenses | $10,355,000 | $7,710,000 | $7,186,000 | $5,643,000 |
| Payables | $6,092,000 | $4,718,000 | $3,691,000 | $2,797,000 |
| Total Tax Payable | $725,000 | $476,000 | - | - |
| Income Tax Payable | $725,000 | $476,000 | - | - |
| Accounts Payable | $2,309,000 | $2,147,000 | $1,667,000 | $1,534,000 |
| Other Current Liabilities | - | - | - | $146,000 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $6,313,000 | $28,458,000 | $18,881,000 | $14,305,000 |
| Total Equity Gross Minority Interest | $6,313,000 | $28,458,000 | $18,881,000 | $14,305,000 |
| Stockholders Equity | $6,313,000 | $28,458,000 | $18,881,000 | $14,305,000 |
| Gains Losses Not Affecting Retained Earnings | $91,000 | $90,000 | $91,000 | $150,000 |
| Other Equity Adjustments | $91,000 | $90,000 | $91,000 | $150,000 |
| Retained Earnings | $-397,561,000 | $-358,730,000 | $-320,889,000 | $-274,225,000 |
| Other | ||||
| Ordinary Shares Number | $44,538,264 | $39,395,712 | $24,494,675 | $19,165,027 |
| Share Issued | $44,538,264 | $39,395,712 | $24,494,675 | $19,165,027 |
| Tangible Book Value | $4,954,000 | $26,719,000 | $16,762,000 | $11,806,000 |
| Invested Capital | $61,966,000 | $69,582,000 | $59,396,000 | $54,221,000 |
| Working Capital | $57,606,000 | $62,473,000 | $54,759,000 | $50,044,000 |
| Capital Lease Obligations | $524,000 | $545,000 | $565,000 | $340,000 |
| Total Capitalization | $61,966,000 | $69,582,000 | $59,396,000 | $54,221,000 |
| Additional Paid In Capital | $403,739,000 | $387,059,000 | $339,655,000 | $288,361,000 |
| Capital Stock | $44,000 | $39,000 | $24,000 | $19,000 |
| Common Stock | $44,000 | $39,000 | $24,000 | $19,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Capital Lease Obligation | $524,000 | $545,000 | $565,000 | $340,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,096,000 | $7,343,000 | $9,216,000 | $6,420,000 |
| Current Accrued Expenses | $4,263,000 | $2,992,000 | $3,495,000 | $2,846,000 |
| Dueto Related Parties Current | $3,058,000 | $2,095,000 | $2,024,000 | $1,263,000 |
| Net PPE | $3,728,000 | $4,079,000 | $3,938,000 | $2,909,000 |
| Accumulated Depreciation | $-3,488,000 | $-4,660,000 | $-4,335,000 | $-4,140,000 |
| Gross PPE | $7,216,000 | $8,739,000 | $8,273,000 | $7,049,000 |
| Leases | $2,537,000 | $2,934,000 | $2,507,000 | $2,309,000 |
| Other Properties | $3,307,000 | $4,706,000 | $4,837,000 | $3,862,000 |
| Machinery Furniture Equipment | $1,372,000 | $1,099,000 | $929,000 | $878,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $10,898,000 | $12,645,000 | $13,102,000 | $11,792,000 |
| Raw Materials | $118,000 | $136,000 | $60,000 | $0 |
| Treasury Shares Number | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-28,667,000 | $-42,584,000 | $-41,468,000 | $-42,620,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-28,219,000 | $-41,595,000 | $-40,857,000 | $-40,748,000 |
| Cash Flow From Continuing Operating Activities | $-28,219,000 | $-41,595,000 | $-40,857,000 | $-40,748,000 |
| Operating Gains Losses | $888,000 | $-7,580,000 | $-12,000 | $1,228,000 |
| Investing Activities | ||||
| Capital Expenditure | $-448,000 | $-989,000 | $-611,000 | $-1,872,000 |
| Investing Cash Flow | $846,000 | $4,451,000 | $-599,000 | $-1,872,000 |
| Cash Flow From Continuing Investing Activities | $846,000 | $4,451,000 | $-599,000 | $-1,872,000 |
| Net Other Investing Changes | $1,294,000 | $5,440,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $11,823,000 | $42,919,000 | $46,341,000 | $34,400,000 |
| Financing Cash Flow | $25,750,000 | $43,057,000 | $46,267,000 | $40,852,000 |
| Cash Flow From Continuing Financing Activities | $25,750,000 | $43,057,000 | $46,267,000 | $40,852,000 |
| Net Other Financing Charges | $-3,759,000 | $-369,000 | $-289,000 | $-3,617,000 |
| Net Common Stock Issuance | $11,823,000 | $42,919,000 | $46,341,000 | $34,400,000 |
| Common Stock Issuance | $11,823,000 | $42,919,000 | $46,341,000 | $34,400,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-42,420,000 | $0 | $0 | $-30,000,000 |
| Issuance Of Debt | $60,000,000 | $0 | $0 | $40,000,000 |
| Interest Paid Supplemental Data | $4,716,000 | $4,071,000 | $4,624,000 | $3,394,000 |
| End Cash Position | $51,095,000 | $52,935,000 | $46,994,000 | $42,019,000 |
| Beginning Cash Position | $52,935,000 | $46,994,000 | $42,019,000 | $43,931,000 |
| Effect Of Exchange Rate Changes | $-217,000 | $28,000 | $164,000 | $-144,000 |
| Changes In Cash | $-1,623,000 | $5,913,000 | $4,811,000 | $-1,768,000 |
| Proceeds From Stock Option Exercised | $106,000 | $507,000 | $215,000 | $69,000 |
| Net Issuance Payments Of Debt | $17,580,000 | $0 | $0 | $10,000,000 |
| Net Long Term Debt Issuance | $17,580,000 | $0 | $0 | $10,000,000 |
| Long Term Debt Payments | $-42,420,000 | $0 | $0 | $-30,000,000 |
| Long Term Debt Issuance | $60,000,000 | $0 | $0 | $40,000,000 |
| Net PPE Purchase And Sale | $-448,000 | $-989,000 | $-599,000 | $-872,000 |
| Sale Of PPE | $0 | $0 | $12,000 | $0 |
| Purchase Of PPE | $-448,000 | $-989,000 | $-611,000 | $-872,000 |
| Change In Working Capital | $1,421,000 | $-4,834,000 | $-1,669,000 | $-5,763,000 |
| Change In Payables And Accrued Expense | $1,901,000 | $-1,327,000 | $4,188,000 | $1,515,000 |
| Change In Accrued Expense | $1,760,000 | $-1,809,000 | $4,177,000 | $2,399,000 |
| Change In Payable | $141,000 | $482,000 | $11,000 | $-884,000 |
| Change In Account Payable | $141,000 | $482,000 | $11,000 | $-884,000 |
| Change In Prepaid Assets | $133,000 | $227,000 | $-81,000 | $1,216,000 |
| Change In Inventory | $-503,000 | $-2,972,000 | $-2,718,000 | $-6,073,000 |
| Change In Receivables | $-110,000 | $-762,000 | $-3,058,000 | $-2,421,000 |
| Changes In Account Receivables | $-110,000 | $-762,000 | $-3,058,000 | $-2,421,000 |
| Other Non Cash Items | $3,267,000 | $3,430,000 | $1,648,000 | $2,907,000 |
| Stock Based Compensation | $3,796,000 | $4,362,000 | $5,032,000 | $3,989,000 |
| Deferred Tax | $230,000 | $-144,000 | $0 | $0 |
| Deferred Income Tax | $230,000 | $-144,000 | $0 | $0 |
| Depreciation Amortization Depletion | $1,010,000 | $1,012,000 | $808,000 | $1,187,000 |
| Depreciation And Amortization | $1,010,000 | $1,012,000 | $808,000 | $1,187,000 |
| Amortization Cash Flow | $380,000 | $380,000 | $380,000 | $804,000 |
| Amortization Of Intangibles | $380,000 | $380,000 | $380,000 | $804,000 |
| Depreciation | $630,000 | $632,000 | $428,000 | $383,000 |
| Gain Loss On Sale Of PPE | $0 | $0 | $-12,000 | $0 |
| Net Income From Continuing Operations | $-38,831,000 | $-37,841,000 | $-46,664,000 | $-44,296,000 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-1,000,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-1,000,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | $-316,000 | $420,000 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Sale Of Investment | - | - | - | $0 |
| Purchase Of Investment | - | - | - | - |
Fetched: 2026-06-17